Arrowhead Pharmaceuticals (ARWR) Total Debt (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Total Debt came in at $199.6 million in Q1 2026, down 27.12% YoY from $273.9 million in Q1 2025, and down 1.71% on a QoQ basis from $203.1 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Total Debt (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 10 years of Total Debt data on file, last reported at $199.6 million in Q1 2026.
- Quarterly Total Debt fell 27.12% year-over-year to $199.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.6 million (down 27.12% YoY) and the FY2025 annual result came in at $254.9 million, down 35.17% from the prior year.
- Total Debt slipped to $199.6 million in Q1 2026, from $203.1 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $409.4 million in Q4 2024 to a low of $199.6 million in Q1 2026.
- A 3-year average of $282.1 million and a median of $254.9 million in 2025 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2025 — Total Debt tumbled 50.39% — and 2026, when it dropped 27.12%.
- Tracing ARWR's Total Debt over 3 years: stood at $409.4 million in 2024, then plunged by 50.39% to $203.1 million in 2025, then decreased by 1.71% to $199.6 million in 2026.
- The last three Total Debt figures came in at $199.6 million (Q1 2026), $203.1 million (Q4 2025), and $254.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 221.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 221.40 Mn |
| Mar 31, 2026 | 199.64 Mn |
| Dec 31, 2025 | 203.11 Mn |
| Sep 30, 2025 | 254.88 Mn |
| Jun 30, 2025 | 240.33 Mn |
| Mar 31, 2025 | 273.93 Mn |
| Dec 31, 2024 | 409.41 Mn |
| Sep 30, 2024 | 393.18 Mn |
| Sep 30, 2019 | 2.70 Mn |
| Jun 30, 2019 | 2.70 Mn |
| Mar 31, 2019 | 2.70 Mn |
| Dec 31, 2018 | 2.30 Mn |
| Sep 30, 2018 | 2.10 Mn |
| Jun 30, 2018 | 2.16 Mn |
| Mar 31, 2018 | 2.22 Mn |
| Dec 31, 2017 | 2.27 Mn |
| Sep 30, 2017 | 2.33 Mn |
| Jun 30, 2017 | 2.38 Mn |
| Mar 31, 2017 | 2.43 Mn |
| Dec 31, 2016 | 2.48 Mn |